Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus SUPRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus SUPRAX.
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER vs SUPRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis and death.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g IV every 8 hours for pseudomonal infections; 500 mg to 1 g IV every 8-12 hours for uncomplicated UTIs.
400 mg orally once daily or 200 mg orally every 12 hours.
None Documented
None Documented
1.5–2.0 hours in normal renal function; prolonged to 15–30 hours in ESRD.
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 11-15 hours in severe renal impairment (CrCl <20 mL/min).
Primarily renal (80–90% unchanged via glomerular filtration); biliary/fecal <1%.
Renal: 50-55% unchanged in urine; biliary/fecal: 10-20% (biliary excretion); remainder metabolized or excreted via feces.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic